Gilde Healthcare strengthens US Venture&Growth team with Rich Wilmot as partner - Gilde Healthcare

Gilde Healthcare strengthens US Venture&Growth team with Rich Wilmot as partner

June 8, 2023
Boston, MA (US)

Gilde Healthcare, a leading transatlantic investment firm specialized in the healthcare sector, today announced the appointment of Rich Wilmot as a Partner in its US Venture&Growth team. Mr. Wilmot brings over 15 years of experience in digital health and healthtech investing to the firm.

Wilmot’s appointment comes at an exciting time as Gilde Healthcare continues to expand its presence in the US market and to strengthen its investment capabilities in the rapidly evolving healthcare landscape. As a Partner, Mr. Wilmot will play an important role in driving Gilde Healthcare’s investment strategy and furthering its mission to deliver better care at lower cost.

“We are thrilled to welcome Rich Wilmot to our US team as a Partner,” said Geoff Pardo, General Partner at Gilde Healthcare. “His extensive experience and deep understanding of healthcare delivery, digital health and the wider healthtech sector make him an important addition to our firm. Rich’s strategic vision and proven track record of successful investments will greatly contribute to our mission of driving innovation and improving patient outcomes.”

Prior to joining Gilde Healthcare, Mr. Wilmot was responsible for creating and managing the corporate venture program at Philips, where he built an industry leading portfolio, investing in many companies during his seven years of leadership. Prior to joining Philips, Mr. Wilmot spent five years at Partners HealthCare investing in healthtech companies. His expertise spans all key areas of digital innovation in the healthcare industry including the areas of telemedicine, healthcare analytics, remote patient monitoring and digital therapeutics.

“I am excited to join Gilde Healthcare and work alongside a team of highly skilled professionals who are committed to making a difference in the healthcare industry,” said Wilmot. “Gilde Healthcare’s dedication to investing in companies that drive positive change aligns perfectly with my passion for advancing healthcare through innovative solutions. I look forward to contributing to the firm’s continued success and impact.”

Wilmot’s appointment reinforces Gilde Healthcare’s commitment to attracting top talent and further strengthens its ability to identify and support promising investment opportunities in the US market. With his profound knowledge and extensive network, Mr. Wilmot will enhance the firm’s capabilities in identifying disruptive companies and partnering with visionary entrepreneurs.

Media contact:
Geoff Pardo – General Partner Gilde Healthcare US
email: pardo@gildehealthcare.com
phone: +1 (617) 407 4865

Pieter van der Meer – Managing Partner Gilde Healthcare
email: vandermeer@gildehealthcare.com
phone: +31 30 219 2565

About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor managing over €2.5 billion across two fund strategies: Venture&Growth and Private Equity. The Venture&Growth fund of Gilde Healthcare invests in fast growing companies active in digital health, medtech and therapeutics, based in Europe and North America. The Private Equity fund of Gilde Healthcare participates in profitable lower mid-market healthcare companies based in North-Western Europe. For more information, visit the company’s website at www.gildehealthcare.com.

Gilde Healthcare company NIZO participates in national consortium investing in precision fermentation scale-up facility

The Netherlands is strengthening its position as a global leader in cellular agriculture with the launch of two independent, open-access scale-up facilities. These facilities, developed in a collaboration between NIZO Food Research, Cultivate at Scale...
February 4, 2025

Gilde Healthcare company GT Medical Technologies raises $37 million in to advance GammaTile® for patients with operable brain tumors

GT Medical Technologies, Inc. (GT MedTech), a medical device company with a corporate purpose of improving the lives of patients with brain tumors, today announced the company has completed a $37 million first close of...
January 17, 2025

Alleviant Medical Secures $90 Million Financing to Expand Interventional Heart Failure Pivotal Trial Program

Alleviant Medical, Inc., a privately held medical device company developing a no-implant atrial shunt for heart failure, today announced a $90 million financing to fund its second pivotal trial. Led by Gilde Healthcare, the round also...
January 14, 2025